Ferring, Aventis Trim Claims In DDAVP Antitrust Class Action

Law360, New York (October 18, 2012, 8:06 PM EDT) -- A New York federal judge on Wednesday narrowed claims brought by a proposed class of indirect purchasers of the anti-diuretic drug DDAVP who allege Ferring BV and a Sanofi SA unit suppressed generic competition by fraudulently acquiring a patent on the medication.

U.S. District Judge Cathy Seibel granted part of a motion to dismiss filed by Ferring and Aventis Pharmaceuticals Inc., throwing out the indirect purchasers’ bid for an injunction under federal antitrust laws, as well as several unjust enrichment claims brought under state laws....
To view the full article, register now.